oncology
Data published on novel molecules for leukaemia treatment
April 27, 2021Manufacturing and Production oncology
STORM Therapeutics have published new data in Nature on targeting RNA modifying enzymes for the development of new anti-cancer therapeutics, …
Enhertu now available via Cancer Drugs Fund following NICE decision
April 20, 2021Manufacturing and Production AstraZeneca, breast cancer, oncology
AstraZeneca and Daiichi Sankyo have announced that NICE has approved Enhertu (trastuzumab deruxtecan) for use within the Cancer Drugs Fund …
TILT Biotherapeutics & MSD to collaborate on adenoviral cancer immunotherapy trial
April 14, 2021Research and Development clinical trial, oncology
TILT Biotherapeutics today announced a clinical trial collaboration agreement with MSD, to evaluate TILT’s adenoviral cancer immunotherapy, TILT-123, in combination …
Exscientia enter first-ever AI cancer drug into Phase I trials
April 9, 2021Medical Communications AI, Evotec, Exscientia, cancer treatment, oncology, pharma, pharma news
Exscientia and Evotec have announced that they are entering an AI-designed immuno-oncology drug into Phase I trials for the first …
Novartis and Artios Pharma to collaborate on DDR cancer therapies
April 7, 2021Research and Development Novartis, RLT, oncology
Novartis and Artios Pharma have announced a global research collaboration to discover and validate next generation DNA damage response (DDR) …
EC approves combination treatment for kidney cancer
March 31, 2021Research and Development Cancer, Europe, oncology
The European Commission (EC) has approved Ipsen’s Cabometyx in combination with Opdivo as a first-line treatment for advanced renal cell …
Astellas Pharma and Seagen cancer treatment gets MAA acceptance from EMA
March 26, 2021Medical Communications EMA, oncology
Astellas Pharma and Seagen Inc. have announced that the EMA has accepted their marketing authorisation application (MAA) for enfortumab vedotin, …
Incyte biliary tract cancer treatment approved in Japan
March 23, 2021Manufacturing and Production EMA, Japan, oncology
The Japanese Ministry of Health, Labour, and Welfare (MHLW) have approved Incyte’s Pemazyre (pemigatinib) for the treatment of patients with …
Accord Healthcare launches thalidomide for multiple myeloma treatment
March 23, 2021Manufacturing and Production MHRA, oncology
Accord Healthcare has announced the UK launch of a generic thalidomide, which is used in combination with melphalan and prednisone, …
Novartis prostate cancer treatment sees positive Phase III results
March 23, 2021Manufacturing and Production Novartis, oncology
Novartis has today announced positive results from its Phase III VISION study with 177Lu-PSMA-617, seeing significant improvements in overall survival …
Roche lung cancer treatment reports promising results in Phase III
March 22, 2021Sales and Marketing Roche, oncology
Roche’s IMpower010 study, evaluating Tecentriq (atezolizumab) compared with best supportive care, has shown significant improvement in disease-free survival (DFS) in …
NICE recommends new triple therapy for multiple myeloma patients
March 19, 2021Medical Communications NHS England, NICE, oncology
A new second line triple therapy is to be offered to NHS patients in England with multiple myeloma, following a …
AstraZeneca & MSD ovarian cancer drug combination approved by NICE
March 19, 2021Medical Communications AstraZeneca, MSD, NICE, oncology
A new precision drug combination, olaparib with bevacizumab, will now be available on the Cancer Drugs Fund (CDF) for ovarian …
Complix and I-Mab sign deal to develop alphabody cancer therapies
March 11, 2021Cancer, Complix, oncology
Biopharmaceutical company Complix has signed a drug discovery deal with I-Mab Biopharma, a clinical-stage company focused on the discovery, development, …
Gilead and Jounce Therapeutics forge immuno-oncology partnership worth a potential $700m+
September 2, 2020Research and Development, Sales and Marketing Gilead, jounce, oncology, pharma
Gilead and Jounce Therapeutics have come together in a new immuno-oncology partnership potentially worth over $700 million. The primary drive …
Latest content
FibroFind appoints Lee Borthwick as CEO
